UNT Libraries Special Collections - 14 Matching Results

Search Results

Birth Outcomes Following Zidovudine Therapy in Pregnant Women

A published article by Morbidity and Mortality about the birth outcomes after treating HIV positive pregnant women with zidovudine (ZDV).

Date: June 10, 1994

Creator: Massachusetts Medical Society

[News Release: Reports on AZT Use by Pregnant Women with HIV]

A news release from Burroughs Wellcome Co. discussing a new study that indicates that AZT therapy can help reduce incidence of maternal transmission of HIV.

Date: 199X

Creator: Burroughs Wellcome Co.

[Press Release: AZT Reduces Rate of Maternal Transmission of HIV]

A press release from the National Institute of Allergy and Infectious Disease discussing how AZT therapy reduces the transmission of HIV from infected mothers to their babies during child birth.

Date: February 21, 1994

Creator: National Institute of Allergy and Infectious Disease

[Document: Burroughs Wellcome Reaction to Data Indicating AZT Reduce Rate of Maternal Transmission of HIV]

A document from Burroughs Wellcome Co. discussing the use of AZT therapy to reduce the transmission of HIV from infected mothers to infants.

Date: 199X

Creator: Burroughs Wellcome Co.

[News Release: Retrovir Indicated to Prevent Transmission of HIV from Pregnant Women to Their Babies]

A news release from Burrough Wellcome Co. announcing that the U.S. Food and Drug Administration released Retrovir (AZT) for therapy to prevent the transmission of HIV from infected mothers to their babies.

Date: August 9, 1994

Creator: Burrough Wellcome Co.

Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community

An article published by the NEJM exploring the sociodemographic differences in prophylactic therapy of HIV infected individuals.

Date: February 16, 1994

Creator: NEJM

ATIN: AIDS TARGETED INFORMATION

A document discussing the effectiveness of AZT, a drug designed to slow the progression of HIV to AIDS.

Date: February 1993

Long-Term Follow-Up of Zidovudine Therapy in Asymptomatic HIV Infection: Results of Multicenter Cohort Study

Research published in the Journal of Acquired Immune Deficiency Syndromes that explained that zidovudine (AZT) is only beneficial to people with HIV/AIDS within the first year of treatment and that after three years there were no sustained clinical benefit.

Date: 1994

Creator: Journal of Acquired Immune Deficiency Syndromes

[News Release: "Quality of Life" in Patients Receiving Retrovir]

A document discussing the use of zidovudine (AZT) as a way of slowing HIV's progression to AIDS and how AZT may impact the patients' quality of life.

Date: February 17, 1994

Creator: Burroughs Wellcome Co.

[Informational Document: Retrovir Fact File]

An informational document from Burroughs Wellcome Co. providing health and medical reporters with additional information about Retrovir.

Date: July 22, 1994

Creator: Burrough Wellcome Co.

[Press Release: Lancet Publication of Concorde Study]

A press release discussing a study released by Lancet Publications that questions when the appropriate time to start HIV therapy on infected individuals is.

Date: 199X-04-07

Creator: Burrough Wellcome Co.

[News Release: FDA Advisory Committe Recommends Approval of Retrovir (AZT) for HIV-Positive Pregnant Wome and Infants]

A news release from Burrough Wellcome Co. about their brand of zidovudine (AZT), Retrovir, being approved by the FDA to reduce the risk of HIV transmission from pregnant mothers to their infants.

Date: 1987

Creator: Burroughs Wellcome Co.

[News Release: Italian Study Supports Clinical Benefit to Early Therapy With AZT]

A news release from Burroughs Wellcome Co. explaining that an Italian study verified the clinical benefits of Burrough Wellcome's brand of zidovudine (AZT) as being helpful in preventing the onset of AIDS in HIV infected individuals.

Date: March 1994

Creator: Burroughs Wellcome Co.

[News Release: Italian Study Supports Clinical Benefit to Early Therapy with AZT]

A news release from Burrough Wellcome Co. about the clinical benefits of their brand of zidovudine (AZT), Retrovir, in slowing the progression of HIV to AIDS.

Date: March 1994

Creator: Burrough Wellcome Co.

UNT Libraries Special Collections - 14 Matching Results

Search Results

Add Filters

Applied Filters

Birth Outcomes Following Zidovudine Therapy in Pregnant Women

[News Release: Reports on AZT Use by Pregnant Women with HIV]

[Press Release: AZT Reduces Rate of Maternal Transmission of HIV]

[Document: Burroughs Wellcome Reaction to Data Indicating AZT Reduce Rate of Maternal Transmission of HIV]

[News Release: Retrovir Indicated to Prevent Transmission of HIV from Pregnant Women to Their Babies]

Racial Differences in the Use of Drug Therapy for HIV Disease in an Urban Community

ATIN: AIDS TARGETED INFORMATION

Long-Term Follow-Up of Zidovudine Therapy in Asymptomatic HIV Infection: Results of Multicenter Cohort Study

[News Release: "Quality of Life" in Patients Receiving Retrovir]

[Informational Document: Retrovir Fact File]

[Press Release: Lancet Publication of Concorde Study]

[News Release: FDA Advisory Committe Recommends Approval of Retrovir (AZT) for HIV-Positive Pregnant Wome and Infants]

[News Release: Italian Study Supports Clinical Benefit to Early Therapy With AZT]

[News Release: Italian Study Supports Clinical Benefit to Early Therapy with AZT]